Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424.

The long-term results confirmed the findings from the initial reportfor efficacy suggesting OS and PFS outcomes with the RT-TMZ regimen exceeding historical control control groups treated with radiation alone. Toxicity was acceptable.